Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus

NCT01954147 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a combination of umbilical cord mesenchymal stem cells and the medication liraglutide can help manage type 2 diabetes in adults.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 100 people Planned (estimated).

Who can join Ages 35–65 · all sexes

Timeline Started 2013-10 · est. completion 2015-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT01954147 ↗

Description as written by the study sponsor.

Umbilical cord mesenchymal stem cells (SC) transplantation was a novel therapy for diabetes mellitus, with less side effects and more advantages. Clinical trials had verified that good metabolic control would be achieved when Liraglutide (GLP-1) was added to the conventional therapies. The investigators hypothesized that the combined therapy of umbilical cord mesenchymal stem cells transplantation and Liraglutide in type 2 diabetes mellitus will aid the differentiation of stem cells into insulin-producing cells, improve the survival of differentiated cells, protect the residual beta-cells and improve insulin secreting function, so as to achieve a favorable glucose homeostasis.

Treatments tested

GLP-1 Drug

GLP-1 therapy
SC Biologic

Stem cell infusion
Standard Medical Treatment also known as SMT Other

Standard Medical Treatment

Main thing measured	HbA1C
Sponsor	Diabetes Care Center of Nanjing Military Command
Conditions studied	Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01954147 ↗